Suppliers / Anhui Poly Pharm

Anhui Poly Pharm

China Updated 9 July 2026

Anhui Poly Pharm is an API manufacturer based in China. It holds 12 active US drug master files and 5 valid CEPs across a filed portfolio of 14 molecules. Its GMP standing is certified by US FDA. Its most recent recorded inspection, by US FDA, closed on 27 February 2025 as VAI.

12
active US DMFs
5
valid CEPs
2
registered plants 1 with an FDA FEI number
2
filings across 1 regulators
These figures were checked against the regulators' own files on 25 July 2026
Plants
1 of 1 confirmed
Inspections
1 of 1 confirmed
Sources: FDA Establishment Registration, read 4 May 2026. FDA drug inspection classifications, read 4 May 2026.

Inspection history

  • 27 February 2025 VAI US FDA

NAI means no action indicated, VAI means voluntary action indicated, and OAI means official action indicated.

Registered plants

Site FDA FEI
Anqing, China Not on file
China, China 3020871572

What they file, and where

Molecule Regulators Docs
Cyclophosphamide EDQM, US FDA 2
Gadobutrol EDQM, US FDA 2
Voriconazole EDQM, US FDA 2
Allopurinol US FDA 1
Apremilast US FDA 1
Crisaborole US FDA 1
Gadoteric Acid US FDA 1
Gadoteridol US FDA 1
Ioversol US FDA 1
Magnesium US FDA 1
Show all 14 molecules on file
Magnesium Hydroxide EDQM 1
Semaglutide US FDA 1
Sodium Nitroprusside EDQM 1
Tecovirimat US FDA 1

Also appears on these molecule pages

Filings and GMP by regulator

Regulator Filings GMP certificates
MINSA (CR) 2 None
US FDA None 1

Comparing suppliers?

Choose your molecules and target markets. Anhui Poly Pharm comes back tiered against every other supplier able to file there.

Start for free
No sales call.

Open risk flags

  • The most recent inspection outcome was VAI, on 27 February 2025.

Sources on this page

FDA
Drug master files, establishment registration, inspection classifications
EDQM
Certificates of suitability
EudraGMDP and national regulators
GMP certificates